10-Q quarterly report · filed Nov 5, 2026

Celcuity Inc. (CELC) Q3 2026 10-Q Quarterly Report

Short answer

Celcuity Inc. (CELC) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$73M
−67.4% YoY · +7.0% QoQ
EPS (diluted)
−$1.33
−46.2% YoY · +7.6% QoQ

Source: XBRL data from the Celcuity Inc. (CELC) Q3 2026 10-Q on SEC EDGAR. USD.

Celcuity Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly product revenue $0, unchanged YoY, as REVTORPYK shipments began September 30, 2026
  • Net loss $73.3M vs $43.8M YoY, operating loss $77.3M vs $42.8M
  • Worst cost trend: SG&A $39.8M, up 220% YoY, driven by commercialization spending
  • Cash, equivalents and short-term investments $642.7M; operating cash use $176.7M through nine months
  • Cash runway expected through 2029, with commercialization and clinical-development spending increasing

Risk Factors

  • New regulatory risk: August 2026 sNDA for PIK3CA-mutated patients may face delay, rejection, narrower labeling, or additional data requirements
  • Regulatory and compliance risk: FDA noncompliance could trigger recalls, approval withdrawal, fines, injunctions, or criminal penalties
  • Market risk: REVTORPYK faces competition from alpelisib, capivasertib, everolimus, and endocrine regimens
  • Pricing and reimbursement risk: Proposed Medicare MFN rebate models could begin January 1, 2027
  • Intellectual-property risk: Generic competition could follow patent challenges and substantially reduce REVTORPYK revenue

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Celcuity Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.